Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

Analyst Ratings

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.25 (1,462.50% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2015MLV & Co.Initiated CoverageBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/15/2016        
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.18)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/17/2015Q215($0.22)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2015($0.37)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014($0.21)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/22/2014($0.15)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/11/2014($0.15)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161($0.14)($0.14)($0.14)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immune Pharmaceuticals (NASDAQ:IMNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
DateHeadline
07/27/16 07:26 AMNoteworthy Analyst's Rating to Observe: Boston Scientific Corporation (NYSE:BSX) , Immune Pharmaceuticals Inc ... - Street Updates
07/27/16 07:26 AMStock under consideration: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
07/26/16 07:34 AMStocks Trending Alert: Ross Stores Inc. (ROST), Immune Pharmaceuticals, Inc. (IMNP), Raytheon Company (RTN) - iStreetWire
07/26/16 07:34 AMPreview of Analysts Recommendation: Bristol-Myers Squibb Company (NYSE:BMY) , Immune Pharmaceuticals Inc ... - Street Updates
07/26/16 07:34 AMReview of Analysts Ranking: Novavax, Inc. (NASDAQ:NVAX) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Street Updates
07/26/16 07:34 AMCurrent Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) PT Means Stock Is Worth Almost $3 - Review Fortune
07/22/16 07:35 AMStocks Buzz: Progressive (PGR), Immune Pharmaceuticals (IMNP) Twilio (TWLO) - iStreetWire
07/22/16 07:35 AMAnalyst Recommendations Review: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
07/20/16 02:38 PMNotable Analyst's Ranking Preview: Abbott Laboratories (NYSE:ABT) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Street Updates
07/20/16 07:37 AMAnalyst's Valuable Buzzers: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Immune Pharmaceuticals Inc ... - Street Updates
07/20/16 07:37 AMEquity Roundup: Stock Performance Focus on Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Press Telegraph
07/20/16 07:37 AMImmune Pharma (IMNP) Enters Amended Agreement with NPT; Will Form Pain-Neurology Subsidiary - StreetInsider.com
07/19/16 04:09 PMIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of -
07/19/16 10:43 AMImmune Pharma (IMNP) Enters Amended Agreement with NPT; Will Form Pain-Neurology Subsidiary
07/19/16 08:30 AMIMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet - [PR Newswire] - NEW YORK, July 19, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP)("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into an amended agreement with NPT, a syndicate of experienced healthcare investors, on July 18, 2016. According to the amended agreement Immune will form a pain-neurology subsidiary, which will own AmiKet® intellectual property. Immune Pharmaceuticals Inc. (IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
07/18/16 09:52 AMWere Analysts Bullish Immune Pharmaceuticals Inc (NASDAQ:IMNP) This Week? - Consumer Eagle
07/18/16 09:52 AMPerformance watch list: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
07/14/16 08:07 AMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 08:07 AMNoteworthy Stocks: Endo International plc (NASDAQ:ENDP) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Street Updates
07/14/16 08:07 AMImmune Pharmaceuticals Inc (NASDAQ:IMNP) Warned Of Possible NASDAQ Delisting - Journal Transcript
07/13/16 07:32 AMWatching Unusual Volume on Shares of: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Engelwood Daily
07/12/16 08:59 AMImmune Pharmaceuticals, Inc. (NASDAQ:IMNP) Insiders Look Optimistic About Prospects - Review Fortune
07/12/16 08:59 AMStock under consideration: Immune Pharmaceuticals (IMNP) - News Oracle
07/11/16 04:42 PMCompany Stock Focus for Immune Pharmaceuticals Inc. (NASDAQ:IMNP): Which Way Will Shares Head? - Press Telegraph
07/11/16 04:42 PMImmune Pharmaceuticals Inc (IMNP) Updated Price Targets - FTSE News
07/11/16 09:20 AMNext Weeks Broker Price Targets For Immune Pharmaceuticals Inc (IMNP) - Fiscal Standard
07/08/16 07:30 AMRevenue Estimates for Investors: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
07/07/16 07:29 AMCan Immune Pharmaceuticals Inc. (NASDAQ:IMNP) Improve on the Earnings Front? - Engelwood Daily
07/07/16 07:29 AMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/07/16 07:29 AMStock Rating Watch and Earnings Insight for Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Press Telegraph
07/07/16 07:29 AMAnalysts: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) stock is worth $2 - Review Fortune
07/06/16 04:26 PMIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or -
07/01/16 04:39 PMImmune Pharmaceuticals Inc (IMNP) Current Analyst Ratings - Fiscal Standard
07/01/16 05:05 AMIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/30/16 07:29 AMNews Fact on Vanguard Level- Comcast (NASDAQ:CMCSA), Immune Pharmaceuticals (NASDAQ:IMNP), Amazon.com ... - Seneca Globe
06/30/16 07:29 AMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Company Rating and Target Watch - Telanagana Press
06/30/16 07:29 AMRatings Analysis of: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
06/29/16 07:27 AMShare Update and Earnings Review for Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Press Telegraph
06/28/16 04:33 PMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 04:33 PMImmune Pharma (IMNP) Announces Positive Results from Azixa Combo in Tumor Reduction - StreetInsider.com
06/23/16 07:31 AMHot Stock under Consideration: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
06/23/16 07:31 AMAnalysts Offer Insights on Healthcare Companies: Immune Pharmaceuticals Inc (NASDAQ: IMNP), Curis Inc. (NASDAQ ... - Analyst Ratings
06/23/16 07:31 AMCurrent Analysts Rating Update: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Skyline Medical Inc. (NASDAQ:SKLN) - Street Updates
06/22/16 04:42 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.27%
06/21/16 04:19 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%
06/21/16 08:00 AMVista Partners Publishes June 2016 Macroeconomic & Investment Newsletter - [Marketwired] - Vista Partners has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts, investment considerations, ...
06/20/16 09:52 AMImmune Pharmaceuticals Inc (IMNP) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:06 AMImmune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 - [PR Newswire] - NEW YORK, June 20, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper, Chief Executive Officer, will be presenting at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 11:00 AM local time in the Astor room at the St Regis Hotel, New York, NY. The presentation will be webcast and available on our website (www.immunepharma.com) after the conference.
06/15/16 04:40 PMAllergan plc Ordinary Shares (NYSE:AGN) & Immune Pharmaceuticals (NASDAQ:IMNP) Investor's Alert - Wall Street 24
06/14/16 09:26 AMImmune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

Social

About Immune Pharmaceuticals

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company's oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMNP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.40
  • 50 Day Moving Average: $0.43
  • 200 Day Moving Average: $0.44
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $16.38M
  • Beta: 1.46
  • Current Year EPS Consensus Estimate: $-0.56 EPS
  • Next Year EPS Consensus Estimate: $-0.21 EPS
Additional Links:
Immune Pharmaceuticals (NASDAQ:IMNP) Chart for Saturday, July, 30, 2016